[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-obstructive-pulmonary-disease-exacerbation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-obstructive-pulmonary-disease-exacerbation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,73,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100596563","phase-3-non-invasive-ventilation-or-cpap-in-osa-copd-following-admission-for-an-acute-hypercapnic-respiratory-failure-100596563",false,"NCT07047092","Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hypercapnic Respiratory Failure","Inclusion Criteria:\n\n1. Age ≥ 18 and \\\u003C 85 years\n2. Patient with a diagnosis of COPD according to GOLD guidelines\n3. Patient admitted for an acute exacerbation of COPD requiring acute NIV or invasive ventilation or high-flow therapy (pH \\\u003C7.35 with PaCO2 \\>45mmHg\u002F6kPa)\n4. Patient that has been weaned from acute NIV or invasive ventilation or high flow therapy\n5. Patient with an overnight polygraphy or polysomnography performed 2 to 30 days following weaning from acute NIV or invasive ventilation showing an obstructive apneahypopnea index \\>=15\u002Fh. For patients already diagnosed with OSA, results from their prior sleep study will be retrieved. If not accessible, overnight polygraphy or polysomnography will be repeated.\n6. Affiliated to the National Health Patients affiliated or, beneficiary of social security, excluding AME (Aide Médicale d'État)\n7. Patient who has read and understood the information letter and signed the consent form\n\nExclusion Criteria:\n\n1. Patient with NIV treatment\n2. Patients who decline any use of NIV or CPAP in the home setting\n3. Significant psychiatric disorder or dementia that would prevent adherence to study protocol\n4. Tobacco use \\\u003C10 pack-year\n5. Expected survival \\\u003C12 months due to any condition other than COPD.\n6. Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)\n7. Pregnant or breastfeeding women\n8. Patient already involved in an interventional research protocol that would impact the outcome measured in the current protocol.","ALL","18 Years","84 Years",{"count":19,"type":20},386,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Chronic obstructive pulmonary disease (COPD) is a major public health problem with 212.3 million prevalent cases of COPD worldwide and 3.3 million deaths related to COPD in 2019. Obstructive sleep apnoea (OSA) is the most common sleep disordered breathing. It is estimated that almost 1 billion adults have OSA worldwide.\n\nGiven the increasing prevalence of obesity, co-morbid OSA is frequently seen in patients with COPD. Co-morbid OSA has been shown to increase mortality, to reduce quality of life and to favour acute exacerbation of COPD. For those admitted for a life-threatening exacerbation of COPD requiring an intensive care admission for acute hypercapnic failure, they are more likely to get readmitted. For those admitted for an acute exacerbation in any ward, they are more likely to be re-admitted for another exacerbation within 180-days if their OSA is not treated.\n\nUnfortunately, data regarding the best management of OSA in patients with co-morbid COPD are lacking as they were often excluded from clinical trials involving patients with COPD. Therefore, CPAP or NIV are administered without scientific evidence establishing which treatment is the most appropriate.",[26,27],"Chronic Obstructive Pulmonary Disease Exacerbation","Obstructive Sleep Apnea Exacerbation",[29,30,31,32],"Chronic Obstructive Pulmonary Disease","Obstructive Sleep Apnea","Continuous Positive Airway Pressure","Non-invasive Ventilation","RECRUITING","2026-06-05",{"date":36,"type":37},"2026-06-09","ACTUAL",{"date":39,"type":37},"2026-06-03",{"date":41,"type":20},"2030-10",{"name":43,"class":44},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100439883","the-catalina-study-100439883","NCT05008081","The CATALINA Study","An International Multi-centre Prospective Cohort Study in Patients Hospitalized for an Acute Exacerbation of COPD","Inclusion Criteria:\n\n* Age 18 years and older\n* Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test with an FEV1\u002FFVC \\\u003C 0.7)\n* Current hospitalization with suspicion of an acute exacerbation of COPD (AECOPD)\n* Inclusion within 48 hours post hospital admission\n* Voluntary written informed consent of the participant or his\u002Fher representative obtained prior to any study procedure\n\nExclusion Criteria:\n\n* Patients unwilling or unable to comply with study procedures\n* Patients not requiring treatment with systemic corticosteroids, antibiotics or both as a minimum therapy for the index AECOPD\n* Patients with a confirmed positive test result for COVID19, or those highly suspected based on clinical examination",{"count":54,"type":20},1000,"1 Year","OBSERVATIONAL","The CATALINA study is a prospective cohort study embedded within CICERO (Collaboration In COPD ExaceRbatiOns, a European Respiratory Society supported Clinical Research Collaboration), designed to collect standardised, longitudinal clinical data and biological samples in 20 centres across Europe and beyond.",[26],[60,61,62],"COPD","Exacerbation","Hospitalization","2026-05-19",{"date":65,"type":37},"2026-05-22",{"date":67,"type":37},"2022-10-25",{"date":69,"type":20},"2028-03",{"name":71,"class":44},"Wim Janssens",22,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":45},"100602579","neutrophil-to-lymphocyte-ratio-in-acute-exacerbation-of-chronic-obstructive-pulmonary-disease-100602579","NCT07125352","Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Marker of Severity and Prognosis","Inclusion Criteria:\n\n* Patients aged 18 and above, Patients who will be admitted at the Chest department, Ain-Shams University Hospitals, diagnosed with AECOPD based on the Global Initiative for Chronic Obstructive Lung Disease 2024 criteria\n\nExclusion Criteria:\n\n* Patients who refused treatment.\n* COPD patients with Malignancy, hematological disorders",{"count":81,"type":20},190,"Chronic obstructive pulmonary disease (COPD) stands as one of the leading causes of mortality worldwide. Acute exacerbations of COPD (AECOPD) lead to rapid respiratory function decline and worsened disease status. Despite recent studies, the ability of the neutrophil-to-lymphocyte ratio (NLR) to predict outcomes in patients with COPD remains controversial. It remains controversial whether NLR can predict clinical outcomes in hospitalized patients with AECOPD. Therefore, this study was conducted to investigate the predictive value of NLR for severity, adverse outcomes in hospitalized patients with AECOPD, and predicting treatment response in patients with AECOPD",[26],"2025-08-13",{"date":86,"type":37},"2025-08-15",{"date":88,"type":37},"2025-05-20",{"date":90,"type":20},"2026-03",{"name":92,"class":44},"Ain Shams University",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100524214","improved-diagnostics-treatment-and-follow-up-of-acute-exacerbation-of-chronic-obstructive-pulmonary-disease-100524214","NCT06105814","Improved Diagnostics, Treatment and Follow-up of Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Improved Diagnostics, Treatment and Follow-up of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPEXNOR)","COPEXNOR","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Admitted to the emergency room with a tentative diagnosis of AECOPD, and at least two of the following criteria, more than the daily variation,\n\n  * Increased dyspnea\n  * Increased cough\n  * Increased sputum production\n  * Need for change in medication due to AECOPD\n* Signed informed consent. Among patients with temporal or permanent reduced ability to consent, close relatives and\u002For family members must be asked and may approve or reject participation on behalf of the patient. In cases where close relatives\u002Ffamily members are not available, study personnel may include patients according to conscious judgment.\n* Patients will be informed about the study and included by dedicated and approved study personnel (study nurses or study doctors), not by the treating health personnel.\n\nExclusion Criteria:\n\n* Pulmonary embolism, segmental or larger\n* Refractory septic shock (meeting the Sepsis-3 definition of septic shock, and requiring vasopressors ≥ 0.5 mcg\u002Fkg\u002Fmin noradrenaline or equivalent dose of other vasopressor(s)\n* Glasgow Coma Scale score 3\n* Patients not eligible for lower airways sampling within the first 24 hours of admission\n* Palliative situation with life expectancy \\\u003C 1 week",{"count":102,"type":20},200,[104],"NA","Chronic obstructive pulmonary disease (COPD) is a chronic and often progressive pulmonary disease, where inflammation and recurrent infections are key pathophysiological contibutors in disease progression. Acute exacerbations of COPD (AECOPD) are often treated with antibiotics, even though only about 50% are caused by bacteria, and the evidence for benefit of empiric antibiotic treatment in AECOPD is conflicting. Microbiological sampling is often insufficient in the setting of AECOPD, and there is a lack of biomarkers distinguishing AECOPD caused by bacteria from those not caused by bacteria, leaving the clinician with few tools to guide the use of antibiotics. Overuse of antibiotics is the main driver of antimicrobial resistance (AMR), a major global public health threat, and obtaining the correct microbiological diagnose is important in guiding treatment of AECOPD.\n\nCOPEXNOR seeks to examine which samples give the highest microbiological yield in AECOPD, comparing induced sputum to nasopharyngeal swabs. We will also compare conventional microbiological diagnostics to modern rapid molecular microbiological tests, to evaluate if faster microbiological diagnosis improves antibiotic stewardship. The study aims to define the microbiological etiology causing AECOPD in the Norwegian COPD-population, and examine the lung microbiome over time. COPEXNOR will explore biomarkers in sputum and blood that can be useful for differentiating patients who will benefit from antibiotic treatment from patients who will not.",[26,107,108],"Pneumonia","Respiratory Tract Infections","NOT_YET_RECRUITING","2023-10-23",{"date":112,"type":37},"2023-10-30",{"date":114,"type":20},"2024-01-01",{"date":116,"type":20},"2030-12-31",{"name":118,"class":44},"Vestre Viken Hospital Trust"]